FDA grants accelerated approval to Inovio's Voceryq, the first US plasmid DNA immunotherapy, for adult RRP

In an open-label trial of 32 adults, 7 of 26 patients with at least three baseline surgeries needed no surgery in the year after treatment; the approval rests on that intermediate endpoint and confirmatory trials are required.